Pertuzumab-mediated Cardiotoxicity: A Single Center Study. by Özgür Özyilkan, Haldun Müderrisoğlu, Şenol Demırcan, Ahmet Sezer, Ahmet Sümbül, Ayşenur Uçar, Aynur Acıbuca

Subjects: Get full text

Dual HER2 blockade in the first-line treatment of metastatic breast cancer - A retrospective population-based observational study in Danish patients by Thomas Christensen, Tobias Berg, Lise Birk Nielsen, Michael Andersson, Maj-Britt Jensen, Ann Knoop

Subjects: “…Pertuzumab…”
Get full text

Combination of Pertuzumab and Trastuzumab in the Treatment of HER2-Positive Early Breast Cancer: A Review of the Emerging Clinical Data by Jagosky M, Tan AR

Subjects: Get full text

Lapatinib and capecitabine as third-line therapy in young woman with advanced breast cancer by Michela Donadio

Subjects: Get full text

Triple HER2-blockade with lapatinib, trastuzumab, and pertuzumab for treatment of HER2 positive metastatic breast cancer with lymphangitic carcinomatosis: A case study by Kazuki Nozawa, Daiki Takatsuka, Yuka Endo, Nanae Horisawa, Yuri Ozaki, Ayumi Kataoka, Haruru Kotani, Akiyo Yoshimura, Masaya Hattori, Masataka Sawaki, Hiroji Iwata

Subjects: Get full text

A randomized, double-blind, parallel control study to evaluate the biosimilarity of QL1209 with Perjeta® in healthy male subjects by Yuanyuan Sun, Heng Yang, Xiaoyan Yang, Shuang Yang, Can Guo, Honghui Chen, Chang Cui, Yuxia Xiang, Guoping Yang, Guoping Yang, Guoping Yang, Guoping Yang, Guoping Yang, Jie Huang

Subjects: Get full text

Circular HER2 RNA positive triple negative breast cancer is sensitive to Pertuzumab by Jie Li, Maoguang Ma, Xuesong Yang, Maolei Zhang, Jingyan Luo, Huangkai Zhou, Nunu Huang, Feizhe Xiao, Bingquan Lai, Weiming Lv, Nu Zhang

Subjects: Get full text

A cost-consequence analysis of adding pertuzumab to the neoadjuvant combination therapy in HER2-positive high-risk early breast cancer in Italy by Alberto Zambelli, Marina Cazzaniga, Nicla La Verde, Elisabetta Munzone, Ippazio Cosimo Antonazzo, Lorenzo Giovanni Mantovani, Serena Di Cosimo, Anna Mancuso, Daniele Generali, Paolo Angelo Cortesi

Subjects: Get full text

The HER2 S310F Mutant Can Form an Active Heterodimer with the EGFR, Which Can Be Inhibited by Cetuximab but Not by Trastuzumab as well as Pertuzumab by Jung Won Shin, Soohyun Kim, Suji Ha, Byungsan Choi, Seongyeong Kim, Seock-Ah Im, Tae-Young Yoon, Junho Chung

Subjects: Get full text

EXPERIENCE OF USING PERTUZUMAB IN ANTICANCER THERAPY FOR HER2-POSITIVE BREAST CANCER by O. I. Kit, L. Yu. Vladimirova, E. A. Kalabanova, A. E. Storozhakova, S. N. Kabanov, T. A. Snezhko, I. S. Mitashok, Ya. V. Svetitskaya, N. Yu. Samaneva, I. S. Kornilova, Yu. V. Przhedetskiy, V. V. Pozdnyakova, N. A. Abramova, I. L. Popova, N. M. Tikhanovskaya, A. A. Lyanova, K. A. Novoselova, L. A. Ryadinskaya

Subjects: Get full text

Longitudinal assessment of cardiac parameters through MRI in breast cancer patients treated with anti-HER2 therapy by Sainan Cheng, Jianwei Wang, Yawen Wang, Linlin Qi, Fenglan Li, Jianing Liu, Jiaqi Chen, Yang Fan, Lizhi Xie

Subjects: Get full text

Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalency cl... by Abolghasem Allahyari, Ali Ehsanpour, Nafiseh Ansarinejad, Valiollah Mehrzad, Behjat Kalantari, Jahangir Raafat, Mojtaba Ghadiany, Farhad Shahi, Behrooz Gharib, Vahid Moazed, Adnan Khosravi, Mir Hossein Mirpour, Sina Salari, Seyedmohammadreza Mortazavizadeh, Amirabbas Nekoyi, Mohsen Khani, Alireza Sadeghi, Sirus Gharib, Alireza Bary, Mehrzad Mirzania, Shirin Haghighat, Seyed Mohsen Razavi, Seyed Amir Hossein Emami, Mehran Hosseinzadeh, Mahdi Mirbolouk, Sanambar Sadighi, Abdolali Shahrasbi, Ali Esfahani, Masoumeh Gity, Nassim Anjidani, Hamidreza Kafi, Safa Najafi

Subjects: Get full text

Neoadjuvant chemotherapy and HER2 dual blockade including biosimilar trastuzumab (SB3) for HER2-positive early breast cancer: Population based real world data from the Danish Breas... by Tobias Berg, Maj-Britt Jensen, Erik H. Jakobsen, Sami Al-Rawi, Julia Kenholm, Michael Andersson

Subjects: Get full text

Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain by Daniel Rayson, Sonal Gandhi, Anil A. Joy, Christine Brezden-Masley, Karen A. Gelmon, Sandeep Sehdev, David Cescon, Stephen Chia

Subjects: Get full text

The Conundrum of Adjuvant HER2 Treatment Options by Ajaz Bulbul, Ajaz Bulbul, Emilio Araujo-Mino, Emilio Araujo-Mino, Zoneddy Ruiz Dayao

Subjects: Get full text

Takotsubo Syndrome during Pertuzumab and Trastuzumab Therapy for HER2-Positive Metastatic Breast Cancer by Azzurra Irelli, Laura Ceriello, Leonardo Valerio Patruno, Alessandra Tessitore, Edoardo Alesse, Katia Cannita, Donatello Fabiani

Subjects: “…pertuzumab…”
Get full text

Long-term survival in a young woman with recurrent HER2-positive breast cancer. by Gianluca Cotroneo

Subjects: Get full text

Efficacy of lapatinib-capecitabine combination in a patient with multiple metastasis from HER2-positive breast cancer by Maria Moritti, Evaristo Maiello

Subjects: Get full text

Severe Thrombocytopenia from Trastuzumab and Pertuzumab Combination Therapy in a Patient with HER2-Positive Metastatic Rectal Cancer by Dai Okemoto, Toshifumi Yamaguchi, Mariko Yamaguchi, Toru Kadono, Hiroki Yukami, Elham Fakhrejahani, Hiroki Nishikawa

Subjects: Get full text

Pertuzumab Increases 17-AAG-Induced Degradation of ErbB2, and This Effect Is Further Increased by Combining Pertuzumab with Trastuzumab by Juliana Bentes Hughes, Marianne Skeie Rødland, Max Hasmann, Inger Helene Madshus, Espen Stang

Subjects: Get full text